Drugs / FID-022
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06694480 | Jul 2025 → Dec 2027 expected | cancer | Fulgent Pharma LLC. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FID-022 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06694480 ↗ |
| Route | Intravenous | “The study drug is administered through intravenous route.” NCT06694480 ↗ |